

## Finasteride (1%) Formulation

Version 14.0      Revision Date: 2024/04/06      SDS Number: 49649-00024      Date of last issue: 2023/09/30  
Date of first issue: 2015/01/26

---

### 1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Finasteride (1%) Formulation

#### Supplier's company name, address and phone number

Company name of supplier : Organon & Co.

Address : 30 Hudson Street, 33rd floor  
Jersey City, New Jersey, U.S.A 07302

Telephone : +1-551-430-6000

E-mail address : EHSSTEWARD@organon.com

Emergency telephone number : +1-215-631-6999

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

---

### 2. HAZARDS IDENTIFICATION

#### GHS classification of chemical product

Reproductive toxicity : Category 1B

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Testis)

Long-term (chronic) aquatic hazard : Category 3

#### GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H360D May damage the unborn child.  
H373 May cause damage to organs (Testis) through prolonged or repeated exposure if swallowed.  
H412 Harmful to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**  
P201 Obtain special instructions before use.

## Finasteride (1%) Formulation

|                 |                              |                            |   |
|-----------------|------------------------------|----------------------------|---|
| Version<br>14.0 | Revision Date:<br>2024/04/06 | SDS Number:<br>49649-00024 | Date of last issue: 2023/09/30<br>Date of first issue: 2015/01/26 |
|-----------------|------------------------------|----------------------------|---|

P202 Do not handle until all safety precautions have been read and understood.

P260 Do not breathe dust.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

Important symptoms and out- : Dust contact with the eyes can lead to mechanical irritation.  
lines of the emergency as- : Contact with dust can cause mechanical irritation or drying of  
sumed : the skin.  
May form explosive dust-air mixture during processing, handling or other means.

**3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

| Chemical name                          | CAS-No.    | Concentration (% w/w) | ENCS No.       |
|--|------------|-----------------------|----------------|
| Cellulose                              | 9004-34-6  | >= 1 - < 10           |                |
| Starch                                 | 9005-25-8  | >= 1 - < 10           | 8-98           |
| Finasteride                            | 98319-26-7 | >= 1 - < 2.5          |                |
| Titanium dioxide                       | 13463-67-7 | > 0 - < 10            | 1-558, 5-5225  |
| Diiron trioxide                        | 1309-37-1  | > 0 - < 10            | 1-357, 5-5188  |
| Iron oxide                             | 1332-37-2  | > 0 - < 10            | 1-357          |
| Sodium bis(2-ethylhexyl)sulfosuccinate | 577-11-7   | > 0 - < 10            | 2-1623, 2-1620 |

**4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

# SAFETY DATA SHEET



## Finasteride (1%) Formulation



|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue:             |
| 14.0    | 2024/04/06     | 49649-00024 | 2023/09/30                      |
|         |                |             | Date of first issue: 2015/01/26 |

---

|   |   |  |
|---|---|--|
| If inhaled  | : | If inhaled, remove to fresh air.<br>Get medical attention.   |
| In case of skin contact                                     | : | In case of contact, immediately flush skin with soap and plenty of water.<br>Remove contaminated clothing and shoes.<br>Get medical attention.<br>Wash clothing before reuse.<br>Thoroughly clean shoes before reuse.  |
| In case of eye contact                                      | : | If in eyes, rinse well with water.<br>Get medical attention if irritation develops and persists.   |
| If swallowed  | : | If swallowed, DO NOT induce vomiting.<br>Get medical attention.<br>Rinse mouth thoroughly with water.  |
| Most important symptoms and effects, both acute and delayed | : | May damage the unborn child.<br>May cause damage to organs through prolonged or repeated exposure if swallowed.<br>Contact with dust can cause mechanical irritation or drying of the skin.<br>Dust contact with the eyes can lead to mechanical irritation. |
| Protection of first-aiders                                  | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).  |
| Notes to physician  | : | Treat symptomatically and supportively.  |

---

### 5. FIREFIGHTING MEASURES

|   |   |   |
|---|---|---|
| Suitable extinguishing media                  | : | Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical  |
| Unsuitable extinguishing media                | : | None known.   |
| Specific hazards during fire-fighting         | : | Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.<br>Exposure to combustion products may be a hazard to health.                   |
| Hazardous combustion products                 | : | Carbon oxides<br>Metal oxides   |
| Specific extinguishing methods                | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.<br>Use water spray to cool unopened containers.<br>Remove undamaged containers from fire area if it is safe to do so.<br>Evacuate area. |
| Special protective equipment for firefighters | : | In the event of fire, wear self-contained breathing apparatus.<br>Use personal protective equipment.  |

---

### 6. ACCIDENTAL RELEASE MEASURES

|  |   |   |
|--|---|---|
| Personal precautions, protective equipment and emergency | : | Use personal protective equipment.<br>Follow safe handling advice (see section 7) and personal pro- |
|--|---|---|

---

# SAFETY DATA SHEET



## Finasteride (1%) Formulation



|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2023/09/30  |
| 14.0    | 2024/04/06     | 49649-00024 | Date of first issue: 2015/01/26 |

---

- gency procedures : tective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

### 7. HANDLING AND STORAGE

#### Handling

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.
- Avoidance of contact : Oxidizing agents
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working

# SAFETY DATA SHEET



## Finasteride (1%) Formulation



Version 14.0      Revision Date: 2024/04/06      SDS Number: 49649-00024      Date of last issue: 2023/09/30  
Date of first issue: 2015/01/26

place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### Storage

- Conditions for safe storage : Keep in properly labelled containers.  
Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents
- Packaging material : Unsuitable material: None known.

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Threshold limit value and permissible exposure limits for each component in the work environment

| Components       | CAS-No.    | Value type (Form of exposure)                                  | Control parameters / Reference concentration / Permissible concentration | Basis          |
|------------------|------------|--|--|----------------|
| Cellulose        | 9004-34-6  | TWA  | 10 mg/m <sup>3</sup>   | ACGIH          |
| Starch           | 9005-25-8  | TWA  | 10 mg/m <sup>3</sup>   | ACGIH          |
| Finasteride      | 98319-26-7 | TWA  | 0.5 µg/m <sup>3</sup> (OEB 5)  | Internal       |
|                  |            | Wipe limit   | 5 µg/100 cm <sup>2</sup>   | Internal       |
| Titanium dioxide | 13463-67-7 | OEL-M (Respirable particulate matter)                          | 1.5 mg/m <sup>3</sup> (Titanium)   | JP OEL<br>JSOH |
|                  |            | Further information: Group 2B: possibly carcinogenic to humans |  |                |
|                  |            | OEL-M (Total particulate matter)                               | 2 mg/m <sup>3</sup> (Titanium)   | JP OEL<br>JSOH |
|                  |            | Further information: Group 2B: possibly carcinogenic to humans |  |                |
|                  |            | TWA (Respirable particulate matter)                            | 2.5 mg/m <sup>3</sup> (Titanium dioxide)                                 | ACGIH          |
| Iron oxide       | 1332-37-2  | OEL-M (Respirable dust)  | 1 mg/m <sup>3</sup> (Iron)   | JP OEL<br>JSOH |
|                  |            | OEL-M (Total dust)   | 4 mg/m <sup>3</sup> (Iron)   | JP OEL<br>JSOH |

# SAFETY DATA SHEET



## Finasteride (1%) Formulation



Version 14.0      Revision Date: 2024/04/06      SDS Number: 49649-00024      Date of last issue: 2023/09/30  
Date of first issue: 2015/01/26

|                 |           |                                     |                            |                |
|-----------------|-----------|-------------------------------------|----------------------------|----------------|
| Diiron trioxide | 1309-37-1 | OEL-M (Respirable dust)             | 1 mg/m <sup>3</sup> (Iron) | JP OEL<br>JSOH |
|                 |           | OEL-M (Total dust)                  | 4 mg/m <sup>3</sup> (Iron) | JP OEL<br>JSOH |
|                 |           | TWA (Respirable particulate matter) | 5 mg/m <sup>3</sup>        | ACGIH          |

**This substance(s) is not bioavailable and therefore does not contribute to a dust inhalation hazard.**

Titanium dioxide

**Engineering measures** : Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted. Totally enclosed processes and materials transport systems are required. Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type  
Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.  
Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

# SAFETY DATA SHEET



## Finasteride (1%) Formulation



Version 14.0      Revision Date: 2024/04/06      SDS Number: 49649-00024      Date of last issue: 2023/09/30  
Date of first issue: 2015/01/26

---

Physical state : powder

Colour : tan

Odour : odourless

Odour Threshold : No data available

Melting point/freezing point : No data available

Boiling point, initial boiling point and boiling range : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Lower explosion limit and upper explosion limit / flammability limit  
Upper explosion limit / Upper per flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Flash point : Not applicable

Decomposition temperature : No data available

pH : No data available

Evaporation rate : Not applicable

Auto-ignition temperature : No data available

Viscosity  
Viscosity, kinematic : Not applicable

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : log Pow: 3.5  
pH: 7  
Active ingredient

Vapour pressure : Not applicable

Density and / or relative density  
Relative density : No data available

Density : No data available

# SAFETY DATA SHEET



## Finasteride (1%) Formulation



|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2023/09/30  |
| 14.0    | 2024/04/06     | 49649-00024 | Date of first issue: 2015/01/26 |

---

Relative vapour density : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle characteristics  
Particle size : No data available

---

### 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

### 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

#### Components:

##### Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

---



## Finasteride (1%) Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2023/09/30  |
| 14.0    | 2024/04/06     | 49649-00024 | Date of first issue: 2015/01/26 |

---

**Starch:**

|                       |                                |
|-----------------------|--------------------------------|
| Acute oral toxicity   | : LD50 (Rat): > 5,000 mg/kg    |
| Acute dermal toxicity | : LD50 (Rabbit): > 2,000 mg/kg |

**Finasteride:**

|                     |                               |
|---------------------|-------------------------------|
| Acute oral toxicity | : LD50 (Rat): 373 - 828 mg/kg |
|                     | LD50 (Mouse): 486 mg/kg       |

**Titanium dioxide:**

|                           |  |
|---------------------------|--|
| Acute oral toxicity       | : LD50 (Rat): > 5,000 mg/kg  |
| Acute inhalation toxicity | : LC50 (Rat): > 6.82 mg/l<br>Exposure time: 4 h<br>Test atmosphere: dust/mist<br>Assessment: The substance or mixture has no acute inhalation toxicity |

**Diiron trioxide:**

|                     |                             |
|---------------------|-----------------------------|
| Acute oral toxicity | : LD50 (Rat): > 5,000 mg/kg |
|---------------------|-----------------------------|

**Iron oxide:**

|                     |  |
|---------------------|--|
| Acute oral toxicity | : LD50 (Rat): > 5,000 mg/kg<br>Remarks: Based on data from similar materials |
|---------------------|--|

**Sodium bis(2-ethylhexyl)sulfosuccinate:**

|                       |                                |
|-----------------------|--------------------------------|
| Acute oral toxicity   | : LD50 (Rat): 3,080 mg/kg      |
| Acute dermal toxicity | : LD50 (Rabbit): > 5,000 mg/kg |

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Finasteride:**

|         |                      |
|---------|----------------------|
| Species | : Rabbit             |
| Result  | : No skin irritation |

**Titanium dioxide:**

|         |                      |
|---------|----------------------|
| Species | : Rabbit             |
| Result  | : No skin irritation |

**Diiron trioxide:**

|         |          |
|---------|----------|
| Species | : Rabbit |
|---------|----------|

## Finasteride (1%) Formulation

Version 14.0      Revision Date: 2024/04/06      SDS Number: 49649-00024      Date of last issue: 2023/09/30  
Date of first issue: 2015/01/26

---

Method : OECD Test Guideline 404  
Result : No skin irritation

**Iron oxide:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation  
Remarks : Based on data from similar materials

**Sodium bis(2-ethylhexyl)sulfosuccinate:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : Skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Starch:**

Species : Rabbit  
Result : No eye irritation

**Finasteride:**

Species : Rabbit  
Remarks : slight irritation

**Titanium dioxide:**

Species : Rabbit  
Result : No eye irritation

**Diiron trioxide:**

Species : Rabbit  
Result : No eye irritation  
Method : OECD Test Guideline 405

**Iron oxide:**

Species : Rabbit  
Result : No eye irritation  
Method : OECD Test Guideline 405  
Remarks : Based on data from similar materials

**Sodium bis(2-ethylhexyl)sulfosuccinate:**

Species : Rabbit  
Result : Irreversible effects on the eye  
Method : OECD Test Guideline 405

## Finasteride (1%) Formulation

Version 14.0      Revision Date: 2024/04/06      SDS Number: 49649-00024      Date of last issue: 2023/09/30  
Date of first issue: 2015/01/26

---

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****Starch:**

|                 |                     |
|-----------------|---------------------|
| Test Type       | : Maximisation Test |
| Exposure routes | : Skin contact      |
| Species         | : Guinea pig        |
| Result          | : negative          |

**Titanium dioxide:**

|                 |                                 |
|-----------------|---------------------------------|
| Test Type       | : Local lymph node assay (LLNA) |
| Exposure routes | : Skin contact                  |
| Species         | : Mouse                         |
| Result          | : negative                      |

**Diiron trioxide:**

|                 |                |
|-----------------|----------------|
| Exposure routes | : Skin contact |
| Species         | : Guinea pig   |
| Result          | : negative     |

**Iron oxide:**

|                 |  |
|-----------------|--|
| Exposure routes | : Skin contact                         |
| Species         | : Guinea pig                           |
| Result          | : negative                             |
| Remarks         | : Based on data from similar materials |

**Sodium bis(2-ethylhexyl)sulfosuccinate:**

|                 |  |
|-----------------|--|
| Test Type       | : Human repeat insult patch test (HRIPT) |
| Exposure routes | : Skin contact                           |
| Species         | : Humans                                 |
| Result          | : negative                               |

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Cellulose:**

|                       |   |
|-----------------------|---|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES)<br>Result: negative    |
|                       | : Test Type: In vitro mammalian cell gene mutation test<br>Result: negative |

## Finasteride (1%) Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2023/09/30  |
| 14.0    | 2024/04/06     | 49649-00024 | Date of first issue: 2015/01/26 |

---

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

### Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

### Finasteride:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro  
Result: positive  
  
Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Alkaline elution assay  
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Application Route: Oral  
Result: negative

### Titanium dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
Species: Mouse  
Result: negative

### Diiron trioxide:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative

### Iron oxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

### Sodium bis(2-ethylhexyl)sulfosuccinate:

## Finasteride (1%) Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2023/09/30  |
| 14.0    | 2024/04/06     | 49649-00024 | Date of first issue: 2015/01/26 |

---

|                       |   |
|-----------------------|---|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES)<br>Method: OECD Test Guideline 471<br>Result: negative   |
|                       | Test Type: Chromosome aberration test in vitro<br>Method: OECD Test Guideline 473<br>Result: equivocal  |
|                       | Test Type: In vitro mammalian cell gene mutation test<br>Method: OECD Test Guideline 476<br>Result: negative<br>Remarks: Based on data from similar materials |

**Carcinogenicity**

Not classified based on available information.

**Components:****Cellulose:**

|                   |             |
|-------------------|-------------|
| Species           | : Rat       |
| Application Route | : Ingestion |
| Exposure time     | : 72 weeks  |
| Result            | : negative  |

**Finasteride:**

|                   |                         |
|-------------------|-------------------------|
| Species           | : Rat                   |
| Application Route | : Ingestion             |
| Exposure time     | : 2 Years               |
|                   | : 160 mg/kg body weight |
| Result            | : negative              |
| Target Organs     | : Testes                |
| Remarks           | : Benign tumor(s)       |

|                   |                   |
|-------------------|-------------------|
| Species           | : Mouse           |
| Application Route | : Ingestion       |
| Exposure time     | : 19 month(s)     |
| Result            | : negative        |
| Target Organs     | : Testes          |
| Remarks           | : Benign tumor(s) |

**Titanium dioxide:**

|                   |  |
|-------------------|--|
| Species           | : Rat  |
| Application Route | : inhalation (dust/mist/fume)  |
| Exposure time     | : 2 Years  |
| Method            | : OECD Test Guideline 453  |
| Result            | : positive   |
| Remarks           | : The mechanism or mode of action may not be relevant in humans.<br>This substance(s) is not bioavailable and therefore does not contribute to a dust inhalation hazard. |

## Finasteride (1%) Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2023/09/30  |
| 14.0    | 2024/04/06     | 49649-00024 | Date of first issue: 2015/01/26 |

---

**Carcinogenicity - Assessment** : Limited evidence of carcinogenicity in inhalation studies with animals.

**Diiron trioxide:**

**Species** : Rat  
**Application Route** : Intraperitoneal injection  
**Exposure time** : 790 - 914 days  
**Result** : negative

**Iron oxide:**

**Species** : Rat  
**Application Route** : Intraperitoneal injection  
**Exposure time** : 790 - 914 days  
**Result** : negative  
**Remarks** : Based on data from similar materials

**Reproductive toxicity**

May damage the unborn child.

**Components:****Cellulose:**

**Effects on fertility** : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Effects on foetal development** : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Finasteride:**

**Effects on fertility** : Test Type: Fertility/early embryonic development  
Species: Rabbit  
Application Route: Oral  
Fertility: NOAEL: 80 mg/kg body weight  
Result: No effects on fertility

Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Fertility: LOAEL: 80 mg/kg body weight  
Result: positive  
Remarks: There is no evidence that these findings are relevant to humans.

**Effects on foetal development** : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion

## Finasteride (1%) Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2023/09/30  |
| 14.0    | 2024/04/06     | 49649-00024 | Date of first issue: 2015/01/26 |

---

Developmental Toxicity: LOAEL: 0.003 mg/kg body weight  
Result: Teratogenic effects, Embryotoxic effects.

Test Type: Embryo-foetal development  
Species: Monkey  
Application Route: Ingestion  
Developmental Toxicity: LOAEL: 2 mg/kg body weight  
Result: Teratogenic effects

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

**Sodium bis(2-ethylhexyl)sulfosuccinate:**

Effects on fertility : Test Type: Three-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

May cause damage to organs (Testis) through prolonged or repeated exposure if swallowed.

**Components:****Finasteride:**

Exposure routes : Ingestion  
Target Organs : Testis  
Assessment : Causes damage to organs through prolonged or repeated exposure.

**Iron oxide:**

Exposure routes : inhalation (dust/mist/fume)  
Assessment : No significant health effects observed in animals at concentrations of 0.2 mg/l/6h/d or less.

**Repeated dose toxicity****Components:****Cellulose:**

Species : Rat  
NOAEL : >= 9,000 mg/kg  
Application Route : Ingestion

## Finasteride (1%) Formulation

Version 14.0      Revision Date: 2024/04/06      SDS Number: 49649-00024      Date of last issue: 2023/09/30  
Date of first issue: 2015/01/26

---

Exposure time : 90 Days

**Starch:**

Species : Rat  
NOAEL :  $\geq 2,000$  mg/kg  
Application Route : Skin contact  
Exposure time : 28 Days  
Method : OECD Test Guideline 410

**Finasteride:**

Species : Rat  
NOAEL : 20 mg/kg  
LOAEL : 40 mg/kg  
Application Route : Oral  
Exposure time : 1 yr  
Target Organs : Testis

Species : Dog  
NOAEL : 45 mg/kg  
Application Route : Oral  
Exposure time : 1 yr  
Target Organs : Testis

**Titanium dioxide:**

Species : Rat  
NOAEL : 24,000 mg/kg  
Application Route : Ingestion  
Exposure time : 28 Days

Species : Rat  
NOAEL : 10 mg/m<sup>3</sup>  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 2 yr

**Iron oxide:**

Species : Rat  
NOAEL : 4.7 mg/m<sup>3</sup>  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 90 Days  
Method : OECD Test Guideline 413  
Remarks : Based on data from similar materials

**Sodium bis(2-ethylhexyl)sulfosuccinate:**

Species : Rat  
NOAEL : 750 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days



## Finasteride (1%) Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2023/09/30  |
| 14.0    | 2024/04/06     | 49649-00024 | Date of first issue: 2015/01/26 |

---

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Finasteride:**

|           |   |   |
|-----------|---|---|
| Ingestion | : | Symptoms: breast tenderness, breast enlargement, impotence, lip swelling, skin rash |
|-----------|---|---|

---

**12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Cellulose:**

|                  |   |  |
|------------------|---|--|
| Toxicity to fish | : | LC50 ( <i>Oryzias latipes</i> (Japanese medaka)): > 100 mg/l<br>Exposure time: 48 h<br>Remarks: Based on data from similar materials |
|------------------|---|--|

**Finasteride:**

|  |   |  |
|--|---|--|
| Toxicity to fish   | : | LC50 ( <i>Oncorhynchus mykiss</i> (rainbow trout)): 20.4 mg/l<br>Exposure time: 96 h<br>Method: FDA 4.11         |
| Toxicity to daphnia and other aquatic invertebrates                    | : | EC50 ( <i>Daphnia magna</i> (Water flea)): 17.8 mg/l<br>Exposure time: 48 h<br>Method: FDA 4.08                  |
| Toxicity to algae/aquatic plants                                       | : | NOEC ( <i>Pseudokirchneriella subcapitata</i> (green algae)): 49 mg/l<br>Exposure time: 14 h<br>Method: FDA 4.01 |
| Toxicity to fish (Chronic toxicity)                                    | : | NOEC ( <i>Oryzias latipes</i> (Orange-red killifish)): 0.05 mg/l<br>Exposure time: 105 d                         |
| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | : | NOEC ( <i>Daphnia magna</i> (Water flea)): 0.12 mg/l<br>Exposure time: 21 d<br>Method: OECD Test Guideline 211   |
| M-Factor (Chronic aquatic toxicity)                                    | : | 1  |

**Titanium dioxide:**

|                  |   |  |
|------------------|---|--|
| Toxicity to fish | : | LC50 ( <i>Oncorhynchus mykiss</i> (rainbow trout)): > 100 mg/l<br>Exposure time: 96 h<br>Method: OECD Test Guideline 203 |
|------------------|---|--|

## Finasteride (1%) Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2023/09/30  |
| 14.0    | 2024/04/06     | 49649-00024 | Date of first issue: 2015/01/26 |

|   |   |   |
|---|---|---|
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): > 100 mg/l<br>Exposure time: 48 h              |
| Toxicity to algae/aquatic plants                    | : | EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l<br>Exposure time: 72 h |
| Toxicity to microorganisms                          | : | EC50: > 1,000 mg/l<br>Exposure time: 3 h<br>Method: OECD Test Guideline 209       |

**Diiron trioxide:**

|   |   |   |
|---|---|---|
| Toxicity to fish                                    | : | LC50 (Danio rerio (zebra fish)): > 50,000 mg/l<br>Exposure time: 96 h                                   |
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): > 100 mg/l<br>Exposure time: 48 h<br>Method: OECD Test Guideline 202 |
| Toxicity to microorganisms                          | : | EC50: > 10,000 mg/l<br>Exposure time: 3 h   |

**Iron oxide:**

|   |   |  |
|---|---|--|
| Toxicity to fish                                    | : | LC50 (Danio rerio (zebra fish)): > 10,000 mg/l<br>Exposure time: 96 h<br>Remarks: Based on data from similar materials             |
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): > 10,000 mg/l<br>Exposure time: 48 h<br>Remarks: Based on data from similar materials           |
| Toxicity to microorganisms                          | : | EC50: $\geq$ 10,000 mg/l<br>Exposure time: 3 h<br>Method: OECD Test Guideline 209<br>Remarks: Based on data from similar materials |

**Sodium bis(2-ethylhexyl)sulfosuccinate:**

|   |   |   |
|---|---|---|
| Toxicity to fish                                    | : | LC50 (Danio rerio (zebra fish)): 49 mg/l<br>Exposure time: 96 h<br>Method: Directive 67/548/EEC, Annex V, C.1.  |
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): 6.6 mg/l<br>Exposure time: 48 h  |
| Toxicity to algae/aquatic plants                    | : | ErC50 (Desmodesmus subspicatus (green algae)): 82.5 mg/l<br>Exposure time: 72 h<br><br>EC10 (Desmodesmus subspicatus (green algae)): 22 mg/l<br>Exposure time: 72 h |
| Toxicity to daphnia and other                       | : | EC10 (Daphnia magna (Water flea)): 9 mg/l   |

# SAFETY DATA SHEET



## Finasteride (1%) Formulation



Version 14.0      Revision Date: 2024/04/06      SDS Number: 49649-00024      Date of last issue: 2023/09/30  
Date of first issue: 2015/01/26

---

aquatic invertebrates (Chronic toxicity)      Exposure time: 21 d  
Method: OECD Test Guideline 211

Toxicity to microorganisms      :      EC50 (Pseudomonas putida): 164 mg/l  
Exposure time: 16 h

### Persistence and degradability

#### Components:

##### Cellulose:

Biodegradability      :      Result: Readily biodegradable.

##### Finasteride:

Biodegradability      :      Result: Not readily biodegradable.  
Biodegradation: 0 %  
Exposure time: 7 d  
Method: FDA 3.11

Stability in water      :      Hydrolysis: 0 %(5 d)  
Method: FDA 3.09

##### Sodium bis(2-ethylhexyl)sulfosuccinate:

Biodegradability      :      Result: Readily biodegradable.  
Biodegradation: 91.2 %  
Exposure time: 28 d

### Bioaccumulative potential

#### Components:

##### Finasteride:

Partition coefficient: n-octanol/water      :      log Pow: 3.57

##### Sodium bis(2-ethylhexyl)sulfosuccinate:

Partition coefficient: n-octanol/water      :      log Pow: 1.998  
Remarks: Calculation

### Mobility in soil

No data available

### Hazardous to the ozone layer

Not applicable

### Other adverse effects

No data available

## Finasteride (1%) Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2023/09/30  |
| 14.0    | 2024/04/06     | 49649-00024 | Date of first issue: 2015/01/26 |

---

---

**13. DISPOSAL CONSIDERATIONS****Disposal methods**

- Waste from residues : Dispose of in accordance with local regulations.  
Do not dispose of waste into sewer.
- Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.
- 

**14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

- UN number : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
Environmentally hazardous : no

**IATA-DGR**

- UN/ID No. : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
Packing instruction (cargo aircraft) : Not applicable  
Packing instruction (passenger aircraft) : Not applicable

**IMDG-Code**

- UN number : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
EmS Code : Not applicable  
Marine pollutant : Not applicable

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**National Regulations**

Refer to section 15 for specific national regulation.

**Special precautions for user**

Not applicable

## Finasteride (1%) Formulation

|                 |                              |                            |   |
|-----------------|------------------------------|----------------------------|---|
| Version<br>14.0 | Revision Date:<br>2024/04/06 | SDS Number:<br>49649-00024 | Date of last issue: 2023/09/30<br>Date of first issue: 2015/01/26 |
|-----------------|------------------------------|----------------------------|---|

## 15. REGULATORY INFORMATION

**Related Regulations****Fire Service Law**

Not applicable to dangerous materials / designated flammables.

**Chemical Substance Control Law**

Priority Assessment Chemical Substance

| Chemical name   | Number |
|---|--------|
| Sodium 1,4-bis[(2-ethylhexyl)oxy]-1,4-dioxobutane-2-sulfonate | 213    |

**Industrial Safety and Health Law****Harmful Substances Prohibited from Manufacture**

Not applicable

**Harmful Substances Required Permission for Manufacture**

Not applicable

**Substances Prevented From Impairment of Health**

Not applicable

**Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity**

Not applicable

**Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity**

Not applicable

**Substances Subject to be Notified Names**

Article 57-2 (Enforcement Order Table 9)

| Chemical name      | Concentration (%) | Remarks              |
|--------------------|-------------------|----------------------|
| Titanium(IV) oxide | >0 - <10          | -                    |
| docusate sodium    | >0 - <10          | From April 1st, 2026 |
| Iron oxide         | >=1 - <10         | -                    |

**Substances Subject to be Indicated Names**

Article 57 (Enforcement Order Article 18)

| Chemical name | Remarks |
|---------------|---------|
| Iron oxide    | -       |

**Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)**

Not applicable

**Ordinance on Prevention of Hazards Due to Specified Chemical Substances**

Not applicable

**Ordinance on Prevention of Lead Poisoning**

Not applicable

## Finasteride (1%) Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2023/09/30  |
| 14.0    | 2024/04/06     | 49649-00024 | Date of first issue: 2015/01/26 |

---

### **Ordinance on Prevention of Tetraalkyl Lead Poisoning**

Not applicable

### **Ordinance on Prevention of Organic Solvent Poisoning**

Not applicable

### **Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)**

Not applicable

### **Poisonous and Deleterious Substances Control Law**

Not applicable

### **Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof**

Not applicable

### **High Pressure Gas Safety Act**

Not applicable

### **Explosive Control Law**

Not applicable

### **Vessel Safety Law**

Not regulated as a dangerous good

### **Aviation Law**

Not regulated as a dangerous good

### **Marine Pollution and Sea Disaster Prevention etc Law**

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Not classified as marine pollutant

### **Narcotics and Psychotropics Control Act**

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

### **Waste Disposal and Public Cleansing Law**

Industrial waste

### **The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

---

## 16. OTHER INFORMATION

In this SDS, if the concentration of substances subject to notification under the Industrial Safety and Health Law is indicated as a range, it includes cases where it is a trade secret.

# SAFETY DATA SHEET



## Finasteride (1%) Formulation



|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2023/09/30  |
| 14.0    | 2024/04/06     | 49649-00024 | Date of first issue: 2015/01/26 |

---

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
JP OEL JSOH : Japan. The Japan Society for Occupational Health. Recommendation of Occupational Exposure Limits

ACGIH / TWA : 8-hour, time-weighted average  
JP OEL JSOH / OEL-M : Occupational Exposure Limit-Mean

AIIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for

# SAFETY DATA SHEET



## Finasteride (1%) Formulation



|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2023/09/30  |
| 14.0    | 2024/04/06     | 49649-00024 | Date of first issue: 2015/01/26 |

---

safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN